A Microenvironment-Driven Peptide Nanoplatform Enhances Ferroptosis and Antiangiogenic Activity for Triple-Negative Breast Cancer Therapy
ACS Biomaterials Science & Engineering · 2026
DOI: 10.1021/acsbiomaterials.6c00577 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2026. Verfasst von Yuanyuan Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Traditional Chinese Medicine, Shandong Second Medical University, Weifang261053, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Ferroptosis, Nanoparticles, Angiogenesis Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) remains a major clinical challenge due to its aggressive nature and limited therapeutic options. Among emerging therapeutic approaches, ferroptosis induction has attracted increasing attention due to its unique mode of action; however, its efficacy is often restricted by insufficient intratumoral drug accumulation and the abnormal tumor vascular microenvironment. Here, we designed a CREKA-modified peptide, Pep1, to actively target tumor-associated fibrin and increase accumulation in the tumor and further developed a pH-responsive self-assembling nanoplatform, PS/Pep1. PS/Pep1 significantly improved intratumoral drug bioavailability, promoted lipid peroxidation, suppressed glutathione peroxidase 4 (GPX4) activity, and downregulated vascular endothelial growth factor (VEGF) expression, thereby inducing ferroptosis- and apoptosis-mediated tumor cell death while suppressing angiogenesis. Upon exposure to the acidic tumor microenvironment, PS/Pep1 transformed from spherical nanoparticles into aggregates with high aspect ratios, facilitating deep tumor penetration and sustained local retention. In summary, this study presents a smart nanomedicine strategy that integrates active targeting, microenvironment-responsive structural transformation, and the synergistic regulation of ferroptosis-mediated cell death and angiogenesis, providing a promising therapeutic paradigm for TNBC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Traditional Chinese Medicine, Shandong Second Medical University, Weifang261053, China.
- School of Bioscience and Technology, Shandong Second Medical University, Weifang261053, China.
- Department of Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang261053, China.
- School of Medical Laboratory, Shandong Second Medical University, Weifang261053, China.
- School of Medical Sciences, Shandong Second Medical University, Weifang261053, China.
- Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing100039, China.
ORCID-Profile: Jingkun Bai
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Chen, Y., Liu, Y., Sun, X., Li, Q., Chen, Y., Liu, Z., Lin, F., Song, Y., Li, J., Gong, Z., Xiao, X., Sun, C., & Bai, J. (2026). A Microenvironment-Driven Peptide Nanoplatform Enhances Ferroptosis and Antiangiogenic Activity for Triple-Negative Breast Cancer Therapy. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.6c00577
Vancouver
Chen Y, Liu Y, Sun X, Li Q, Chen Y, Liu Z, et al. A Microenvironment-Driven Peptide Nanoplatform Enhances Ferroptosis and Antiangiogenic Activity for Triple-Negative Breast Cancer Therapy. ACS Biomaterials Science & Engineering. 2026. doi:10.1021/acsbiomaterials.6c00577
BibTeX
@article{Chen2026,
author = {Chen, Yuanyuan and Liu, Yun and Sun, Xiumei and Li, Qian and Chen, Yao and Liu, Ziru and Lin, Fantao and Song, Yuanxin and Li, Junjie and Gong, Zhongying and Xiao, Xiaohe and Sun, Changgang and Bai, Jingkun},
title = {A Microenvironment-Driven Peptide Nanoplatform Enhances Ferroptosis and Antiangiogenic Activity for Triple-Negative Breast Cancer Therapy},
journal = {ACS Biomaterials Science & Engineering},
year = {2026},
doi = {10.1021/acsbiomaterials.6c00577}
}
EUVIMED